{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:23:30Z","timestamp":1787909010917,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and objective:<\/jats:bold> Idiopathic pulmonary fibrosis (IPF) is a critical disease, with limited treatments available. Clinical practices show that traditional Chinese medicine (TCM) has certain efficacy. This study was preliminarily to evaluate the efficacy and safety of TCM treatment based on syndrome differentiation in IPF.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A study design of exploratory, multi-centers, randomized, double-blinded, placebo controlled trial has been adopted. A total of 80 IPF patients from four sub-centers were enrolled. All the patients were randomly assigned into TCM group (TCMG) or control group (CG) in 1:1. Patients in TCMG were given CM granules, as patients in CG given with the placebo of CM granule. All the patients received a 26-week treatment. The efficacy was assessed by acute exacerbations (AEs) of IPF, pulmonary function, clinical symptoms, dyspnea scores (mMRC), health-related quality of life (HRQoL), 6-min walk test (6MWT) and all-cause mortality. Safety has also been assessed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 67 patients completed the trial with 35 in TCM group and 32 in control group. Meaningful differences have been observed in mean changes in AEs (\u22121.56 times; 95% CI, \u22122.69 to \u22120.43, <jats:italic>p<\/jats:italic> = 0.01), DLco% (5.29; 95% CI, 0.76 to 9.81, <jats:italic>p<\/jats:italic> = 0.02), cough scores (\u22120.38 points; 95% CI, \u22120.73 to \u22120.04, <jats:italic>p<\/jats:italic> = 0.03), and 6MWT (30.43\u00a0m; 95% CI, 2.85 to 58.00, <jats:italic>p<\/jats:italic> = 0.03), with no statistical differences in FEV1, FVC, expectoration, chest tightness, Shortness of breath, Fatigue, Cyanosis, mMRC, CAT, SF-36, and SGRQ total scores in 26\u00a0weeks after treatment than before treatment. At of the end of follow-up, a total of 10 patients died, including three and seven in the TCM and control group respectively. And the HR (Hazard ratio) for CM granules in all-cause mortality was 0.39 (95% CI, 0.10\u20131.52). The drug-related adverse events were not observed.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> CM granules, as compared with placebo, could reduce frequencies of AEs, improve pulmonary function, HRQoL, exercise capacity and symptoms and signs for IPF to some extent with acceptable side-effect.<\/jats:p>","DOI":"10.3389\/fphar.2022.1053356","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T04:59:40Z","timestamp":1666933180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiansheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-qing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1590\/S1806-37562018000040001","article-title":"Six-minute walk test in patients with idiopathic pulmonary fibrosis","volume":"44","author":"Baddini-Martinez","year":"2018","journal-title":"J. Bras. Pneumol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12890-017-0444-0","article-title":"Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis","volume":"17","author":"Bahmer","year":"2017","journal-title":"BMC Pulm. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1465-9921-10-101","article-title":"Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial","volume":"10","author":"Behr","year":"2009","journal-title":"Respir. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12916-016-0567-9","article-title":"Guidelines or guidance for better idiopathic pulmonary fibrosis management?","volume":"14","author":"Behr","year":"2016","journal-title":"BMC Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/s-0043-123035","article-title":"German guideline for idiopathic pulmonary fibrosis - update on pharmacological therapies 2017","volume":"72","author":"Behr","year":"2018","journal-title":"Pneumologie"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1378\/chest.14-0492","article-title":"Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis","volume":"146","author":"Collard","year":"2014","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.rmr.2017.07.017","article-title":"French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version","volume":"34","author":"Cottin","year":"2017","journal-title":"Rev. Mal. Respir."},{"key":"B9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/resp.14194","article-title":"Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia","volume":"27","author":"Cox","year":"2022","journal-title":"Respirology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1164\/rccm.201905-0958LE","article-title":"Trends in idiopathic pulmonary fibrosis-related mortality in the United States: 2000-2017","volume":"200","author":"Dove","year":"2019","journal-title":"Am. J. Resp. Crit. care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1183\/09031936.00131813","article-title":"6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis","volume":"43","author":"du Bois","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12931-021-01634-x","article-title":"Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: A longitudinal analysis of the Swedish IPF registry","volume":"22","author":"Gao","year":"2021","journal-title":"Respir. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.4187\/respcare.05875","article-title":"Short- and long-term reliability of the 6-minute walk test in People with idiopathic pulmonary fibrosis","volume":"63","author":"Holland","year":"2018","journal-title":"Respir. Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European respiratory society\/American thoracic society technical standard: Field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","article-title":"Japanese guideline for the treatment of idiopathic pulmonary fibrosis","volume":"56","author":"Homma","year":"2018","journal-title":"Respir. Investig."},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1183\/13993003.01504-2015","article-title":"Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada","volume":"48","author":"Hopkins","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5694\/mja17.00799","article-title":"Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary","volume":"208","author":"Jo","year":"2018","journal-title":"Med. J. Aust."},{"key":"B18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12931-016-0400-1","article-title":"Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis","volume":"17","author":"Kakugawa","year":"2016","journal-title":"Respir. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4046\/trd.2018.0091","article-title":"Korean guidelines for diagnosis and management of interstitial lung diseases: Part 2. Idiopathic pulmonary fibrosis","volume":"82","author":"Lee","year":"2019","journal-title":"Tuberc. Respir. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir. Res."},{"key":"B22","volume-title":"Medical treatments for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis","author":"Pitre","year":"2022"},{"key":"B23","first-page":"1163","article-title":"Diagnostic criteria of traditional Chinese medicine syndromes for diffuse interstitial lung disease (2012Edition)","volume":"53","year":"2012","journal-title":"J. Traditional Chin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/crj.12631","article-title":"Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"12","author":"Qiu","year":"2018","journal-title":"Clin. Respir. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.201201-0006PP","article-title":"Idiopathic pulmonary fibrosis: Clinically meaningful primary endpoints in phase 3 clinical trials","volume":"185","author":"Raghu","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12890-015-0165-1","article-title":"Clinical and economic burden of idiopathic pulmonary fibrosis: A retrospective cohort study","volume":"16","author":"Raimundo","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1378\/chest.15-0530","article-title":"Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline","volume":"149","author":"Salisbury","year":"2016","journal-title":"Chest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/thoraxjnl-2012-202580","article-title":"Hot of the breath: Mortality as a primary end-point in IPF treatment trials: The best is the enemy of the good","volume":"67","author":"Wells","year":"2012","journal-title":"Thorax"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e050004","DOI":"10.1136\/bmjopen-2021-050004","article-title":"Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: A systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.joim.2019.12.005","article-title":"Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial","volume":"18","author":"Yu","year":"2020","journal-title":"J. Integr. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1053356\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T04:59:45Z","timestamp":1666933185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1053356\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":34,"alternative-id":["10.3389\/fphar.2022.1053356"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1053356","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"article-number":"1053356"}}